+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Screening for and surveillance of Barrett's esophagus is clinically indicated



Screening for and surveillance of Barrett's esophagus is clinically indicated



Digestive Diseases 25(3): 197-202



Barrett's esophagus (BE) is a complication of chronic gastroesophageal reflux disease (GERD) and is the precursor of esophageal adenocarcinoma (EA), through a progression from intestinal metaplasia (IM), through high-grade dysplasia (HGD). Although the progression from BE to EA seems to be infrequent (0.5% per year), endoscopic and bioptic surveillance would play a significant role in the evaluation of HGD and the detection of EA in early, curable stage, improving survival rates after treatments. The severity and the duration of GERD could be helpful in the assessment of the risk for BE and to enroll these subjects into screening protocols to detect any dysplastic or neoplastic change. The benefits of screening-surveillance programs could be furthermore enhanced by an improvement in diagnostic methods, such as high-resolution endoscopic techniques and the use of biomarkers for the histological examination seems to play a primary role in the cancer risk stratification; in such way, endoscopic resection techniques (mucosal resection and submucosal dissection) can be considered as a helpful method to stage dysplastic changes in BE.

(PDF emailed within 0-6 h: $19.90)

Accession: 055670979

Download citation: RISBibTeXText

PMID: 17827939

DOI: 10.1159/000103884


Related references

How far to go? Screening and surveillance in Barrett's esophagus. American Journal of Managed Care 7(1 Suppl): S19-S26, 2001

Screening and surveillance of Barrett's esophagus. Current Gastroenterology Reports 11(3): 195-201, 2009

Screening and surveillance for Barrett esophagus. JAMA Internal Medicine 175(2): 159-160, 2015

Surveillance and screening for Barrett esophagus and adenocarcinoma. Journal of Clinical Gastroenterology 39(4 Suppl 2): S33-S41, 2005

Barrett's esophagus: novel strategies for screening and surveillance. Therapeutic Advances in Chronic Disease 10: 2040622319837851, 2019

Not all of Barrett's esophagus surveillance protocols are created equal: the dangers of retrospective outcome research in the treatment of Barrett's esophagus. Gastrointestinal Endoscopy 80(6): 1203, 2015

Evolving screening and surveillance techniques for Barrett's esophagus. World Journal of Gastroenterology 25(17): 2045-2057, 2019

Barrett's esophagus: update on screening, surveillance, and treatment. Archives of Internal Medicine 159(13): 1411-1416, 1999

Screening and surveillance in Barrett's esophagus: a call to action. Clinical Gastroenterology and Hepatology 2(10): 861-864, 2004

Screening and Surveillance for Barrett's Esophagus: Is It Cost-Effective?. Digestive Diseases and Sciences 63(8): 2094-2104, 2018

Barrett's Esophagus: Diagnosis, Screening, Surveillance, and Controversies. Gut and Liver 1(2): 93-100, 2007

The field effect in Barrett's esophagus: can we use it for screening and surveillance?. Endoscopy 45(12): 989-991, 2014

Point-Counterpoint: Screening and Surveillance for Barrett's Esophagus, Is It Worthwhile?. Digestive Diseases and Sciences: -, 2018

Critical appraisal of guidelines for screening and surveillance of Barrett's esophagus. Annals of Translational Medicine 6(13): 259, 2018

The use of optical coherence tomography in screening and surveillance of Barrett's esophagus. Clinical Gastroenterology and Hepatology 3(7 Suppl 1): S8-11, 2005